510(k) Report

510(k) · Cleared

Cleared

EyeArt v2.2.0

K223357510(k) TraditionalCleared Jun 16, 2023226-day reviewClass II21 CFR 886.1100

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Eyenuk, Inc. · PIB Diabetic Retinopathy Detection Device

Cleared on Jun 16, 2023 as substantially equivalent to K200667 (Eyenuk, Inc., 2020) after a 226-day review. Its family tree reaches back 2 generations to 2018.

Decided
Jun 16, 2023
Review
226 days
Class
Class II
Product code
PIB
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN180001 (2018). No later device cites it as a predicate yet.

DEN180001 · IDx-DR · Idx, LLC · 2018K200667 · EyeArt · Eyenuk, Inc. · 202020162018202020222024
  1. Root · 2 generations backDEN180001 IDx-DRIdx, LLC · 2018
  2. 1 generation backK200667 EyeArtEyenuk, Inc. · 2020
  3. This deviceK223357 EyeArt v2.2.0Eyenuk, Inc. · 2023
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN180001IDx-DRIdx, LLC2018—
−1K200667EyeArtEyenuk, Inc.2020—
0 (this device)K223357EyeArt v2.2.0Eyenuk, Inc.2023—
FIG. 1 — Lineage of K223357, 2018–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PIB? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PIB device

  1. #1 K253704 iPredict-DRscore 11.9 · 2 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K200667EyeArt
Summary page 4
…Regulation: 21 CFR 886.1100 Product Code: PIB III. Predicate device Trade name of the device: EyeArt Manufacturer’s Name: Eyenuk, Inc. Premarket notification number: K200667 IV. Device Description EyeArt is a software as a medical device that consists of three components – Client, Server, and Anal…
Eyenuk, Inc.2020—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 5 years and passes through 2 companies; a new generation was cleared every 2.9 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All PIB devices

PIB Diabetic Retinopathy Detection Device: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · PIB

1in 2024

2018: 12020: 12021: 12022: 22023: 12024: 12026 (partial year): 1
2007high 2 (2022) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PIB

Too few PIB 510(k)s in any year since 2007 to give a median.

Recalls per year · PIB

No recall names PIB since 2007.

Adverse event reports per year · PIB

1in 2025

2025: 1
2007high 1 (2025) · low 0 (2007)2025

MAUDE reports naming product code PIB, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20181—00
20190—00
20201—00
20211—00
20222—00
20231—00
20241—00
20250—01
20261—0—

What is it indicated for?

EyeArt is indicated for use by healthcare providers to automatically detect more than mild diabetic retinopathy and vision-threatening diabetic retinopathy (severe non-proliferative diabetic retinopathy or proliferative diabetic retinopathy and/or diabetic macular edema) in eyes of adults diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. EyeArt is indicated for use with Canon CR-2 AF, Canon CR-2 Plus AF, and Topcon NW400 cameras.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K223357: EyeArt v2.2.0.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K223357

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026